Spexis AG operates as a biopharmaceutical company focused on discovering and developing macrocyclic molecules for rare diseases and cancer. The company develops and markets macrocyclic molecule-based therapeutics, including ColiFinR, an inhaled therapeutic for cystic fibrosis that is approved and marketed in Europe, with plans for further global studies. It maintains two macrocycle libraries, Pemfinder and Macrofinder, for drug discovery targeting various molecular targets, and has several pre-clinical leads for different indications. The company seeks development, commercialization, strategic transaction, and financial partnerships for its rare disease and oncology programs. Spexis serves investors, development and commercialization partners, and other firms in the biotechnology and pharmaceutical sectors, as well as financial and strategic transaction partners within the life sciences industry. The company is based in Allschwil, Switzerland.